Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Nephrology Division, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München - Campus Großhadern, Munich, Germany.
J Nephrol. 2019 Dec;32(6):919-926. doi: 10.1007/s40620-019-00642-x. Epub 2019 Aug 30.
The kidney is commonly affected in patients with ANCA-associated vasculitis (AAV), causing end-stage renal disease (ESRD) in 20-40% of cases. Kidney transplantation is the treatment of choice for eligible patients with ESRD due to AAV. This review provides a summary of patient and graft outcome after kidney transplantation in AAV patients, the risk of relapse and the optimal time of transplantation. We also address the rare event of de novo ANCA-associated vasculitis after kidney transplantation and the treatment options.
肾脏在抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)患者中常受影响,导致 20-40%的病例出现终末期肾病(ESRD)。对于因 AAV 导致 ESRD 的合适患者,肾移植是首选治疗方法。本综述总结了 AAV 患者肾移植后的患者和移植物结局、复发风险以及最佳移植时机。我们还讨论了肾移植后新发 ANCA 相关性血管炎的罕见事件和治疗选择。